Lactobacillus gasseri BNR17 and Reduced Abdominal Pain

Research synthesisModerate evidenceSmall effect3 studies · 3 beneficial · 0 neutral · 0 harmful

Across 3 studies, all reported beneficial small-sized effects on reducing abdominal pain in populations with functional constipation, diarrhea-dominant irritable bowel syndrome (IBS), and general IBS. Evidence is from small randomized controlled trials (total n=119), with one study using a high dose of 2 × 5 × 10^9 CFU/day.

Studied populations: adults with functional constipation or IBS (including diarrhea-dominant and general IBS with BMI >23 kg/m²)

Caveats: Available evidence is overwhelmingly positive (3/3 studies beneficial) — clinical literature in this area is subject to publication bias. Evidence base is small (only 3 studies, total n=119) — conclusions should be considered preliminary. Study durations and optimal dose were not consistently reported, limiting generalizability.

Generated Jul 12, 2026

Doses used in studies

CFU/day: 10 billion (median 10 billion, IQR 10 billion–10 billion) — 1 study

Safety in these studies

Overall tolerabilityReported
The abstract does not report any adverse events, side effects, or safety findings. It only describes efficacy outcomes such as symptom improvement, health-related quality of life, colon transit time, and fecal microbiota changes.
from: A double blind, placebo-controlled, randomized clinical trial that breast milk derived-Lac

3 of 3 papersPopulation:

Therapeutic Value of Lactobacillus gasseri 345A in Chronic Constipation.
- 2025-03-03
- RCT · n = 40
- Neurogastroenterology and motility 37(5)
- - Stefan Roos
  - Atti-La Dahlgren
  - Yu-Kang Mao
  - Anton Pallin
  - Andrew M Stanisz
  - Paul Forsythe
  - Wolfgang Kunze
  - Per M Hellström
- PubMed: 40033155
- DOI: 10.1111/nmo.70012
9 Insights on
- Reduced Abdominal Pain
- High evidence
Lactobacillus gasseri showed a significant reduction in abdominal pain, along with a correlation and tendency for an increased number of CSBM.
Effect
Beneficial
Effect size
Small
Significant
Yes
A double blind, placebo-controlled, randomized clinical trial that breast milk derived-Lactobacillus gasseri BNR17 mitigated diarrhea-dominant irritable bowel syndrome
- 2020-09-30
- RCT · n = 24
- Journal of Clinical Biochemistry and Nutrition 62(2)
- - S. Shin
  - Yoon Mi Choi
  - W. Kim
  - S. Hong
  - Jong‐Min Park
  - Joohee Kim
  - O. Kwon
  - E. Lee
  - K. Hahm
- PubMed: 29610559
- DOI: 10.3164/jcbn.17-73
12 Insights on
- Reduced Abdominal Pain
- High evidence
- Rigorous Journal
Health related-QOL analysis showed significant improvement of abdominal pain, distension, disturbed daily life, and mean defecation frequency with BNR17.
Effect
Beneficial
Effect size
Small
Significant
Yes
Effect of Lactobacillus gasseri BNR17 on irritable bowel syndrome: a randomized, double-blind, placebo-controlled, dose-finding trial
- 2017-12-12
- RCT · n = 55
- Food Science and Biotechnology 27(3)
- - J. Y. Kim
  - Y. Park
  - H. Lee
  - M. Park
  - O. Kwon
- PubMed: 30263811
- DOI: 10.1007/s10068-017-0296-7
3 Insights on
- Reduced Abdominal Pain
- High evidence
- Clinical
Among IBS symptoms scores, abdominal pain score was significantly reduced in BNR-H group.
Effect
Beneficial
Effect size
Small
Significant
Yes
Dose
2 × 5 × 10^9 CFU/day (high-dose, BNR-H)

Lactobacillus gasseri BNR17 and Reduced Abdominal Pain

Therapeutic Value of Lactobacillus gasseri 345A in Chronic Constipation.

A double blind, placebo-controlled, randomized clinical trial that breast milk derived-Lactobacillus gasseri BNR17 mitigated diarrhea-dominant irritable bowel syndrome

Effect of Lactobacillus gasseri BNR17 on irritable bowel syndrome: a randomized, double-blind, placebo-controlled, dose-finding trial